Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.
Full description
PRIMARY OBJECTIVES:
I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA).
OUTLINE:
Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes, participants undergo whole body PET/CT. Immediately after the first scan, participants may undergo a second PET/CT without receiving fluorine F 18 DCFPyL.
After completion of study, participants are followed up at 24-72 hours.
Sex
Ages
Volunteers
Inclusion criteria
Biopsy proven prostate adenocarcinoma
Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)
Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation
Post-radiation therapy - American Society for Radiation Oncology (ASTRO) - Phoenix consensus definition
Able to provide written consent
Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG] / World Health Organization [WHO] equivalent)
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal